Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Ancona – page 28

377 clinical trials in Ancona, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Ancona at a glance
377
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

377 trials in Ancona

Open in trial search

Acute lymphocytic leukaemia

Not recruiting

Study on Improving Treatment for Children and Adolescents with Acute Lymphoblastic Leukemia Using Bortezomib, Blinatumomab, and a Drug Combination

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Blinatumomab
  • Sponsor:Universitaetsklinikum Schleswig-Holstein AöR

Acute myeloid leukaemia (in remission)

Not recruiting

Study on the Effectiveness of Decitabine and Venetoclax for Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Decitabine
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Anaemia+1

Not recruiting

Study of SEL120 Monohydrochloride for Treating Anemia in Patients with Lower-Risk Myelodysplastic Syndromes (MDS)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:7,8-Dibromo-5,6-Dihydro-9-Methyl-2-(1-Piperazinyl)-4H-Imidazo[4,5,1-Ij]Quinoline Hydrochloride
  • Sponsor:Gcp-Service International West GmbH

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Dry eye+1

Not recruiting

Study on the Effectiveness and Safety of Ianalumab for Patients with Active Sjögren’s Syndrome

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ianalumab
  • Sponsor:Novartis Pharma AG

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Adrenogenital syndrome

Not recruiting

Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Crinecerfont
  • Sponsor:Neurocrine Biosciences Inc.

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Age-related macular degeneration

Not recruiting

Study on the Effectiveness and Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a 36-Week Refill System

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Psoriasis

Not recruiting

Study on Bimekizumab and Ustekinumab for Children and Teens with Moderate to Severe Plaque Psoriasis

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Bimekizumab
  • Sponsor:UCB Biopharma

Study on the Effectiveness and Safety of Secukinumab for Adults with Moderate to Severe Rotator Cuff Tendinopathy

Not recruiting
Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Dermatitis atopic

Not recruiting

Study on Dose Flexibility of Upadacitinib for Adults with Moderate to Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Italy

The busiest research cities in the country

All 237 cities in Italy

Clinical research in Ancona

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on metastatic colorectal cancer and various advanced cancers including gastric cancer and non-small cell lung cancer. Studies evaluate novel treatment combinations and targeted therapies.

  • Colorectal Cancer Treatments
  • Gastric Cancer Therapies
  • Lung Cancer Innovations

Multiple studies examining new therapeutic approaches for pancreatic adenocarcinoma and advanced solid tumors.

02 Hematologic Disorders

Comprehensive research into blood disorders, including multiple myeloma and chronic myeloid leukemia. Studies focus on novel treatment combinations and targeted therapies.

  • Leukemia Treatments
  • Multiple Myeloma Therapies
  • Stem Cell Transplantation

Evaluation of new therapeutic approaches for various blood cancers and related conditions.

03 Dermatology & Rheumatology

Clinical studies investigating treatments for psoriatic arthritis, hidradenitis suppurativa, and atopic dermatitis. Focus on innovative biological therapies.

  • Inflammatory Skin Conditions
  • Autoimmune Disorders
  • Joint Diseases

Research aimed at improving treatment outcomes for chronic inflammatory conditions.

04 Respiratory Medicine

Studies evaluating treatments for progressive pulmonary fibrosis and severe asthma. Research focuses on improving lung function and disease management.

  • Pulmonary Fibrosis
  • Asthma Management
  • Respiratory Conditions

Development of innovative therapies for chronic respiratory diseases.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.